PMID- 35655778
OWN - NLM
STAT- MEDLINE
DCOM- 20220606
LR  - 20220716
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency 
      Virus-Negative Castleman Disease.
PG  - 899073
LID - 10.3389/fimmu.2022.899073 [doi]
LID - 899073
AB  - Castleman disease (CD) is a rare lymphoproliferative disorder. The mechanistic 
      target of rapamycin (mTOR) pathway is a key regulator of various cellular 
      functions, which may be related with the potential mechanisms of CD occurrence. 
      We retrospectively collected the clinical information of 60 CD patients diagnosed 
      in the First Affiliated Hospital of Zhengzhou University. And FFPE biopsy 
      specimens were collected from 31 patients (12 unicentric CD patients and 19 
      multicentric CD patients) to detect the mTOR pathway protein expression. We are 
      the first to demonstrate that thrombocytopenia and hypoalbuminemia are 
      independent poor prognostic factors for CD. Moreover, mTOR activation was higher 
      in CD compared to reactive lymphoid hyperplasia (used as a control group). This 
      study offers some elucidation for the management and treatment of CD patients.
CI  - Copyright (c) 2022 Qian, Ding, Hou, Wang, Zhang, Zhang, Dong, Zhu, Wang, Li and 
      Zhang.
FAU - Qian, Siyu
AU  - Qian S
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Ding, Mengjie
AU  - Ding M
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Hou, Huting
AU  - Hou H
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Wang, Zeyuan
AU  - Wang Z
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhang, Jieming
AU  - Zhang J
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Dong, Meng
AU  - Dong M
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhu, Linan
AU  - Zhu L
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
FAU - Wang, Guannan
AU  - Wang G
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Li, Wencai
AU  - Li W
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhang, Xudong
AU  - Zhang X
AD  - Department of Oncology, The First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220517
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - *Castleman Disease/diagnosis
MH  - HIV
MH  - Humans
MH  - Rare Diseases
MH  - Retrospective Studies
MH  - TOR Serine-Threonine Kinases
MH  - *Thrombocytopenia
PMC - PMC9152317
OTO - NOTNLM
OT  - Castleman disease
OT  - classifications
OT  - mTOR pathway
OT  - prognosis
OT  - thrombocytopenia
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/04 06:00
MHDA- 2022/06/07 06:00
PMCR- 2022/01/01
CRDT- 2022/06/03 02:18
PHST- 2022/03/18 00:00 [received]
PHST- 2022/04/19 00:00 [accepted]
PHST- 2022/06/03 02:18 [entrez]
PHST- 2022/06/04 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.899073 [doi]
PST - epublish
SO  - Front Immunol. 2022 May 17;13:899073. doi: 10.3389/fimmu.2022.899073. eCollection 
      2022.